Exploring the role of the oncology nurse in cervical cancer screening programs during times of transition

Cervical cancer remains the fourth most prevalent cancer among women worldwide, with approximately 660,000 new diagnoses and 350,000 deaths recorded in 2022. Countries with well-established preventative measures have experienced significant reductions in cervical cancer rates through vaccination and...

Full description

Saved in:
Bibliographic Details
Published inCanadian oncology nursing journal Vol. 35; no. 1; pp. 223 - 232
Main Authors Lamanna, Alessia, Gosselin, Sophie, Buick, Catriona
Format Journal Article
LanguageEnglish
French
Published Canada Canadian Association of Nurses in Oncology 2025
Subjects
Online AccessGet full text
ISSN1181-912X
2368-8076

Cover

Abstract Cervical cancer remains the fourth most prevalent cancer among women worldwide, with approximately 660,000 new diagnoses and 350,000 deaths recorded in 2022. Countries with well-established preventative measures have experienced significant reductions in cervical cancer rates through vaccination and regular screening. In Canada, recent efforts have emphasized the adoption of primary HPV-DNA testing as a primary screening tool in cervical cancer screening programs, replacing the cytology (pap) testing. The COVID-19 pandemic had disrupted these initiatives, posing challenges to screening and vaccination programs. Despite these setbacks, ongoing recovery strategies are underway to mitigate the pandemic's adverse effects. Several challenges regarding this shift also have been identified by countries that have transitioned their respective screening programs to primary HPV-DNA testing. Understanding these unique challenges will be essential for developing strategies to address barriers, such as implementing new technologies, training healthcare providers, and ensuring equitable access to screening. This review seeks to (1) examine the evolution of HPV testing and the transition from cervical cytology (Pap smear) to HPV testing as the primary screening method; (2) assess the long-term impacts of the COVID-19 pandemic on screening, prevention, and HPV vaccination within the Canadian healthcare system; and (3) explore the pivotal role of oncology nurses in advancing education, advocacy, and leadership in cancer prevention.
AbstractList Cervical cancer remains the fourth most prevalent cancer among women worldwide, with approximately 660,000 new diagnoses and 350,000 deaths recorded in 2022. Countries with well-established preventative measures have experienced significant reductions in cervical cancer rates through vaccination and regular screening. In Canada, recent efforts have emphasized the adoption of primary HPV-DNA testing as a primary screening tool in cervical cancer screening programs, replacing the cytology (pap) testing. The COVID-19 pandemic had disrupted these initiatives, posing challenges to screening and vaccination programs. Despite these setbacks, ongoing recovery strategies are underway to mitigate the pandemic’s adverse effects. Several challenges regarding this shift also have been identified by countries that have transitioned their respective screening programs to primary HPV-DNA testing. Understanding these unique challenges will be essential for developing strategies to address barriers, such as implementing new technologies, training healthcare providers, and ensuring equitable access to screening. This review seeks to (1) examine the evolution of HPV testing and the transition from cervical cytology (Pap smear) to HPV testing as the primary screening method; (2) assess the long-term impacts of the COVID-19 pandemic on screening, prevention, and HPV vaccination within the Canadian healthcare system; and (3) explore the pivotal role of oncology nurses in advancing education, advocacy, and leadership in cancer prevention.
Cervical cancer remains the fourth most prevalent cancer among women worldwide, with approximately 660,000 new diagnoses and 350,000 deaths recorded in 2022. Countries with well-established preventative measures have experienced significant reductions in cervical cancer rates through vaccination and regular screening. In Canada, recent efforts have emphasized the adoption of primary HPV-DNA testing as a primary screening tool in cervical cancer screening programs, replacing the cytology (pap) testing. The COVID-19 pandemic had disrupted these initiatives, posing challenges to screening and vaccination programs. Despite these setbacks, ongoing recovery strategies are underway to mitigate the pandemic's adverse effects. Several challenges regarding this shift also have been identified by countries that have transitioned their respective screening programs to primary HPV-DNA testing. Understanding these unique challenges will be essential for developing strategies to address barriers, such as implementing new technologies, training healthcare providers, and ensuring equitable access to screening. This review seeks to (1) examine the evolution of HPV testing and the transition from cervical cytology (Pap smear) to HPV testing as the primary screening method; (2) assess the long-term impacts of the COVID-19 pandemic on screening, prevention, and HPV vaccination within the Canadian healthcare system; and (3) explore the pivotal role of oncology nurses in advancing education, advocacy, and leadership in cancer prevention.Cervical cancer remains the fourth most prevalent cancer among women worldwide, with approximately 660,000 new diagnoses and 350,000 deaths recorded in 2022. Countries with well-established preventative measures have experienced significant reductions in cervical cancer rates through vaccination and regular screening. In Canada, recent efforts have emphasized the adoption of primary HPV-DNA testing as a primary screening tool in cervical cancer screening programs, replacing the cytology (pap) testing. The COVID-19 pandemic had disrupted these initiatives, posing challenges to screening and vaccination programs. Despite these setbacks, ongoing recovery strategies are underway to mitigate the pandemic's adverse effects. Several challenges regarding this shift also have been identified by countries that have transitioned their respective screening programs to primary HPV-DNA testing. Understanding these unique challenges will be essential for developing strategies to address barriers, such as implementing new technologies, training healthcare providers, and ensuring equitable access to screening. This review seeks to (1) examine the evolution of HPV testing and the transition from cervical cytology (Pap smear) to HPV testing as the primary screening method; (2) assess the long-term impacts of the COVID-19 pandemic on screening, prevention, and HPV vaccination within the Canadian healthcare system; and (3) explore the pivotal role of oncology nurses in advancing education, advocacy, and leadership in cancer prevention.
Author Gosselin, Sophie
Lamanna, Alessia
Buick, Catriona
Author_xml – sequence: 1
  givenname: Alessia
  surname: Lamanna
  fullname: Lamanna, Alessia
  organization: student, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto ON; York University, Faculty of Health, School of Nursing, Toronto, ON
– sequence: 2
  givenname: Sophie
  surname: Gosselin
  fullname: Gosselin, Sophie
  organization: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON
– sequence: 3
  givenname: Catriona
  surname: Buick
  fullname: Buick, Catriona
  organization: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto ON; York University, Faculty of Health, School of Nursing, Toronto, ON
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40874108$$D View this record in MEDLINE/PubMed
BookMark eNpdkU1Lw0AQhhdRbK39C7LgxUtgv7LZnkRK_YCCFwVvYZNM0i3Jbtxtiv33rm0VdS4zMO88vC9zgU6ts3CCxoxLlSiSyVM0plTRZEbZ2whNQ1iTWCqlipBzNBJEZYISNUZm8dG3zhvb4M0KsHctYFfvZ2dL17pmh-3gA2BjcQl-a0rd4lLbOONQegD7ddt713jdBVwNB5bpIOxBXttgNsbZS3RW6zbA9Ngn6PV-8TJ_TJbPD0_zu2XSU0FkooAVDFQKpGB1IWmdZsBYIbUSsqhqyiotSV2AAKVoVnEgqtJZwdOqSjnjMz5BtwduPxQdVCXY6KHNe2867Xe50yb_u7FmlTdum1PGs9mMyki4ORK8ex8gbPLOhBLaVltwQ8g5E5JTrpSI0ut_0rUbvI35ck4zkcVEhEbV1W9LP16-38A_AVdAiZA
ContentType Journal Article
Copyright 2025 Canadian Association of Nurses in Oncology (CANO).
2025. This work is published under https://creativecommons.org/licenses/by-nc-sa/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 Canadian Association of Nurses in Oncology (CANO) 2025
Copyright_xml – notice: 2025 Canadian Association of Nurses in Oncology (CANO).
– notice: 2025. This work is published under https://creativecommons.org/licenses/by-nc-sa/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 Canadian Association of Nurses in Oncology (CANO) 2025
DBID NPM
3V.
7RV
7X7
7XB
88E
8FI
8FJ
8FK
8FQ
ABUWG
AFKRA
AN0
ASE
AZQEC
BENPR
CCPQU
COVID
DWQXO
FPQ
FYUFA
GHDGH
K6X
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DatabaseName PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest CBCA Database
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest British Nursing Database
British Nursing Index
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
British Nursing Index (BNI) (1985 to Present)
Health Research Premium Collection
Health Research Premium Collection (Alumni)
British Nursing Index
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Medical Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
CBCA Complete
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
Coronavirus Research Database
British Nursing Index
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2368-8076
EndPage 232
ExternalDocumentID PMC12379916
40874108
Genre Journal Article
GroupedDBID ---
04C
6PF
7RV
7X7
88E
8FI
8FJ
8FQ
AAWTL
ABUWG
ADBBV
ADOJX
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BCNDV
BENPR
BKEYQ
BMSDO
BPHCQ
BVXVI
CCPQU
DWQXO
EBD
ECF
ECT
EIHBH
F5P
FRP
FYUFA
HMCUK
HYE
M1P
NAPCQ
NPM
OK1
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RPM
UKHRP
ZT4
3V.
7XB
8FK
AN0
ASE
AZQEC
COVID
FPQ
K6X
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-p1406-8e2b2e85e0b2fb61f57e22b6a846bdf12da60fbe4e8817d3e08da7b35dd532393
IEDL.DBID BENPR
ISSN 1181-912X
IngestDate Tue Sep 30 17:00:54 EDT 2025
Thu Oct 02 21:35:11 EDT 2025
Tue Oct 07 06:39:32 EDT 2025
Tue Sep 16 01:42:51 EDT 2025
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
French
License 2025 Canadian Association of Nurses in Oncology (CANO).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p1406-8e2b2e85e0b2fb61f57e22b6a846bdf12da60fbe4e8817d3e08da7b35dd532393
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/3174740601?pq-origsite=%requestingapplication%&accountid=15518
PMID 40874108
PQID 3174740601
PQPubID 2041165
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_12379916
proquest_miscellaneous_3246313884
proquest_journals_3174740601
pubmed_primary_40874108
PublicationCentury 2000
PublicationDate 2025-Winter
20250101
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – year: 2025
  text: 2025-Winter
PublicationDecade 2020
PublicationPlace Canada
PublicationPlace_xml – name: Canada
– name: Vancouver
PublicationTitle Canadian oncology nursing journal
PublicationTitleAlternate Can Oncol Nurs J
PublicationYear 2025
Publisher Canadian Association of Nurses in Oncology
Publisher_xml – name: Canadian Association of Nurses in Oncology
SSID ssj0000851800
Score 2.319628
Snippet Cervical cancer remains the fourth most prevalent cancer among women worldwide, with approximately 660,000 new diagnoses and 350,000 deaths recorded in 2022....
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 223
SubjectTerms Cellular biology
Cervical cancer
COVID-19 vaccines
Human papillomavirus
Immunization
Medical screening
Oncology
Pandemics
Supplement
Title Exploring the role of the oncology nurse in cervical cancer screening programs during times of transition
URI https://www.ncbi.nlm.nih.gov/pubmed/40874108
https://www.proquest.com/docview/3174740601
https://www.proquest.com/docview/3246313884
https://pubmed.ncbi.nlm.nih.gov/PMC12379916
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2368-8076
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000851800
  issn: 1181-912X
  databaseCode: RPM
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2368-8076
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000851800
  issn: 1181-912X
  databaseCode: 7X7
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2368-8076
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000851800
  issn: 1181-912X
  databaseCode: BENPR
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LSwMxEB5qC-JFfLtaSwSvi7vZR9KDiEpLEVpELPRWNpsJ9rJb-zj4782k22pFvC0kG5ZMduZL5ss3ADdtozFAjn5O3AobIdp-JkTbN0LIII9imTq2e3-Q9obx8ygZ1WCwvgtDtMq1T3SOWpc5nZHf2jgXi5jUQ-6nHz5VjaLs6rqERlaVVtB3TmJsBxqclLHq0HjsDF5eN6cuBDCku5dCFy7tn85Hf0HL3wzJHyGnewD7FVZkDyvjHkINiyPY7VfZ8GOYbAh0zMI4RkRBVhr3XBZOjfqTOZIGmxQsd07BDpeTnWfMugu7haV3K4rWnK2uLDJXbt4NRHHMUbpOYNjtvD31_Kp0gj-1O6bUl8gVR5lgoLhRaWgSgZyrNLNwQ2kTcp2lgVEYo5Sh0BEGUmdCRYnWSUSqaKdQL8oCz4EZtBhOp6g5Gsoatg1GmcyUUMZuX0LuQXM9f-Nq_c_H39by4HrTbFcupSOyAsul7cPjNAojKWMPzlbTPZ6uJDbGcSAt1AmkB3LLEJsOpIq93VJM3p06tg3FgkDvxf_fdQl7nEr5utOUJtQXsyVeWXyxUC3YESPRqpbOFxGM1oU
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB71IVEuiBZol7bUSHCMSBwndg4Vgj60fewKoVbaW4jjsbqXZOm2Qv1z_LbOeLMLRRW33iI5sSJ7PPON55sZgA-FdxijxKhmbgVZiCKqtC4ir7WJ61SZPLDdB8O8f6lOR9loCX7Pc2GYVjnXiUFRu7bmO_JPZOeUVlw95PPkZ8Rdozi6Om-hUXWtFdx-KDHWJXac4d0vcuGm-yeHtN8fpTw-ujjoR12XgWhCzkUeGZRWoskwttLbPPGZRiltXpFlts4n0lV57C0qNCbRLsXYuErbNHMuS7mAGM27DKsqVQU5f6tfj4bfvi9ueRjQmJAHwwmepFnk6DEo-y8j8y8Td_wSXnTYVHyZCdM6LGGzAc8GXfT9FYwXhD1BsFEwMVG0Pjy3Tah-fScCKUSMG1EHJUTT1SxX14LUE7nM_G1HCZuKWYqkCO3tw0RsNwOF7DVcPskivoGVpm1wC4RHwowuRyfRc5Sy8JhWprLaenKXEtmDnfn6ld15m5Z_pKMH7xfDdFI4_FE12N7SO1LlaZIao3qwOVvucjIr6VGq2BC0ik0PzIONWLzAVbgfjjTjq1CNm0y_ZpD99v__tQdr_YvBeXl-MjzbhueS2wiHm5wdWLm5vsVdwjY39l0nQAJ-PLXM3gNyjBMX
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploring+the+role+of+the+oncology+nurse+in+cervical+cancer+screening+programs+during+times+of+transition&rft.jtitle=Canadian+oncology+nursing+journal&rft.au=Lamanna%2C+Alessia&rft.au=Gosselin%2C+Sophie&rft.au=Buick%2C+Catriona&rft.date=2025-01-01&rft.pub=Canadian+Association+of+Nurses+in+Oncology&rft.issn=1181-912X&rft.eissn=2368-8076&rft.volume=35&rft.issue=1&rft.spage=223
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1181-912X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1181-912X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1181-912X&client=summon